Amicus Therapeutics receives US approval for Fabry disease drug


REUTERS: U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi’s infused Fabrazyme.

(Reporting by Robin Respaut; Editing by Phil Berlowitz)





Read More Here

Be the first to comment on "Amicus Therapeutics receives US approval for Fabry disease drug"

Leave a comment

Your email address will not be published.


*